Cyclooxygenase Inhibitors

"Cyclooxygenase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Descriptor ID	D016861
MeSH Number(s)	D27.505.519.389.310 D27.505.696.663.850.014.040.500.500 D27.505.954.158.030.500 D27.505.954.329.030.500
Concept/Terms	Cyclooxygenase Inhibitors Cyclooxygenase Inhibitors Inhibitors, Cyclo-Oxygenase Inhibitors, Cyclo Oxygenase Inhibitors, Cyclooxygenase Prostaglandin Synthesis Antagonists Antagonists, Prostaglandin Synthesis Inhibitors, Prostaglandin-Endoperoxide Synthase Inhibitors, Prostaglandin Endoperoxide Synthase Prostaglandin Endoperoxide Synthase Inhibitors Prostaglandin Synthase Inhibitors Cyclo-Oxygenase Inhibitors Cyclo Oxygenase Inhibitors Inhibitors, Prostaglandin Synthase

Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Cyclooxygenase Inhibitors [D27.505.519.389.310]
Physiological Effects of Drugs [D27.505.696]
Peripheral Nervous System Agents [D27.505.696.663]
Sensory System Agents [D27.505.696.663.850]
Analgesics [D27.505.696.663.850.014]
Analgesics, Non-Narcotic [D27.505.696.663.850.014.040]
Anti-Inflammatory Agents, Non-Steroidal [D27.505.696.663.850.014.040.500]
Cyclooxygenase Inhibitors [D27.505.696.663.850.014.040.500.500]
Therapeutic Uses [D27.505.954]
Anti-Inflammatory Agents [D27.505.954.158]
Anti-Inflammatory Agents, Non-Steroidal [D27.505.954.158.030]
Cyclooxygenase Inhibitors [D27.505.954.158.030.500]
Antirheumatic Agents [D27.505.954.329]
Anti-Inflammatory Agents, Non-Steroidal [D27.505.954.329.030]
Cyclooxygenase Inhibitors [D27.505.954.329.030.500]

Below are MeSH descriptors whose meaning is related to "Cyclooxygenase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase Inhibitors".

Cyclooxygenase Inhibitors
Cyclooxygenase 2 Inhibitors

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cyclooxygenase Inhibitors" by people in this website by year, and whether "Cyclooxygenase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 39 publications over 15 distinct years, with a maximum of 7 publications in 2002

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
2000	1	0	1
2001	0	1	1
2002	5	2	7
2003	3	1	4
2004	5	1	6
2005	2	0	2
2006	1	2	3
2008	2	1	3
2009	1	0	1
2010	1	2	3
2011	1	1	2
2013	0	2	2
2019	2	0	2
2020	1	0	1

Below are the most recent publications written about "Cyclooxygenase Inhibitors" by people in Profiles.

Irons HR, Salas RN, Bhai SF, Gregorie WD, Harris NS. Prospective Double-Blinded Randomized Field-Based Clinical Trial of Metoclopramide and Ibuprofen for the Treatment of High Altitude Headache and Acute Mountain Sickness. Wilderness Environ Med. 2020 Mar; 31(1):38-43.

View in: PubMed
Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF, Blumenthal RS, McEvoy JW. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019 05 25; 393(10186):2155-2167.

View in: PubMed
Vaidya R, Wilson D, Paris Y, Madore L, Singh R. Use of acetaminophen for patent ductus arteriosus treatment: a single center experience. J Matern Fetal Neonatal Med. 2020 Aug; 33(16):2723-2729.

View in: PubMed
Hussain A, Syed MA, Abbas N, Hanif S, Arshad MS, Bukhari NI, Hussain K, Akhlaq M, Ahmad Z. Development of an ANN optimized mucoadhesive buccal tablet containing flurbiprofen and lidocaine for dental pain. Acta Pharm. 2016 Jun 01; 66(2):245-56.

View in: PubMed
DeFilippis AP, Oloyede OS, Andrikopoulou E, Saenger AK, Palachuvattil JM, Fasoro YA, Guallar E, Blumenthal RS, Kickler TS, Jaffe AS, Gerstenblith G, Schulman SP, Rade JJ. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction. Circ J. 2013; 77(11):2786-92.

View in: PubMed
Gleim S, Stitham J, Tang WH, Li H, Douville K, Chelikani P, Rade JJ, Martin KA, Hwa J. Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis. PLoS One. 2013; 8(6):e67314.

View in: PubMed
Kondratyuk TP, Park EJ, Marler LE, Ahn S, Yuan Y, Choi Y, Yu R, van Breemen RB, Sun B, Hoshino J, Cushman M, Jermihov KC, Mesecar AD, Grubbs CJ, Pezzuto JM. Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol Nutr Food Res. 2011 Aug; 55(8):1249-65.

View in: PubMed
Yang JH, Kondratyuk TP, Jermihov KC, Marler LE, Qiu X, Choi Y, Cao H, Yu R, Sturdy M, Huang R, Liu Y, Wang LQ, Mesecar AD, van Breemen RB, Pezzuto JM, Fong HH, Chen YG, Zhang HJ. Bioactive compounds from the fern Lepisorus contortus. J Nat Prod. 2011 Feb 25; 74(2):129-36.

View in: PubMed
Imazio M, Brucato A, Rampello S, Armellino F, Trinchero R, Spodick DH, Adler Y. Management of pericardial diseases during pregnancy. J Cardiovasc Med (Hagerstown). 2010 Aug; 11(8):557-62.

View in: PubMed
Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD, Mesecar AD. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J. 2010 Jul 15; 429(2):273-82.

View in: PubMed

People

Explore

Similar Concepts

Top Journals